TATYANA TSIPURSKY: Open Payments
NPI 1275506974 · BROOKLYN, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,711 in 103 payments from 12 companies in 2025. Trend: 2023 $1,728 · 2024 $2,204 · 2025 $2,711
Food & beverage: $2,711
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 20 | $556 |
| ABBVIE INC. | 17 | $407 |
| Alkermes, Inc. | 15 | $352 |
| Axsome Therapeutics, Inc. | 11 | $330 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $329 |
| Lundbeck LLC | 11 | $262 |
| E.R. Squibb & Sons, L.L.C. | 6 | $213 |
| Almatica Pharma LLC | 5 | $130 |
| Janssen Pharmaceuticals, Inc | 1 | $43 |
| Vanda Pharmaceuticals Inc. | 2 | $42 |
Products named: REXULTI, VRAYLAR, LYBALVI, Auvelity, CAPLYTA, COBENFY, ABILIFY ASIMTUFII, LOREEV XR.
Industry payments across NY — which companies pay providers there.
